treatment of Lenalidomide

3 trials

Sponsors

National Hospital Organization Disaster Medical Center, Hematology, Respiratory Medicine and Oncology,Faculty of Medicine, Saga University

Conditions

multiple myelomaplasma cell myeloma

Phase 2

The efficacy, safety, and the predictive factors of efficacy of low dose Lenalidomide plus Dexamethasone consolidation therapy followed by very low dose Lenalidomide maintenance therapy for multiple myeloma.

RecruitingJPRN-UMIN000007785

National Hospital Organization Disaster Medical Centermultiple myeloma

Start: 2011-10-01Target: 35Updated: 2026-06-29

Analysis of efficacy and immunomodulatory activity of lenalidomide alone in relapse and refractory multiple myeloma

Active, not recruitingJPRN-UMIN000009927

Hematology, Respiratory Medicine and Oncology,Faculty of Medicine, Saga Universityplasma cell myeloma

Start: 2013-02-01Target: 33Updated: 2026-06-29

Unknown Phase

The efficacy, safety, and the predictive factors of efficacy of Bird therapy

RecruitingJPRN-UMIN000013959

National Hospital Organization Disaster Medical Centermultiple myeloma

Start: 2013-12-01Target: 35Updated: 2026-06-29